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Objectives: To summarise the clinical presentation and outcomes in a series of miniature schnauzers 
diagnosed with histiocytic sarcoma.
Materials and MethOds: Retrospective review of medical records of miniature schnauzers diagnosed with 
histiocytic sarcoma between 2008 and 2019 at two referral centres in the UK. Signalment, clinical 
signs at initial presentation, imaging results and clinico- and histopathological findings, treatment type 
and outcome were recorded. Progression-free survival and overall survival time were calculated.
results: Thirty dogs were included. Twenty-four of 29 dogs undergoing imaging of the thorax had lung 
and/or mediastinal involvement. The median overall survival time for dogs that were not euthanased 
within 3 days of diagnosis was 117 days (range 10 to 790). Three dogs underwent surgery; 13 received 
treatment with lomustine as a sole therapy - with partial responses documented on imaging in five of 
six dogs and 11 of 13 showing clinical improvement.
clinical significance: Histiocytic sarcoma should be considered as a differential diagnosis for miniature 
schnauzers with pulmonary masses. Although responses to treatment were common, they were usually 
short-lived because of the aggressive nature of the disease.
INTRODUCTION
Canine histiocytic tumours encompass a group of neoplasms with 
diverse cellular origins and different biological behaviours. His-
tiocytic sarcoma (HS) is a malignant neoplasm with an aggressive 
clinical course. Three forms of HS have been recognised, based 
on the clinical presentation and cellular origin of the tumour: 
localised, disseminated and haemophagocytic (Moore et al. 2006, 
Fulmer & Mauldin 2007, Skorupski et al. 2007, Dervisis et al. 
2017). Localised and disseminated HS originate from dendritic 
cells, while haemophagocytic HS originates from macrophages. 
Localised HS describes neoplastic histiocytic cells that can arise 
from various tissues, including skin/subcutaneous tissue, skeletal 
muscle, joint/bone, liver, spleen, lymph node, lungs, mediasti-
num, central nervous system and eye. (Craig et al. 2002, Nara-
njo et al. 2007, Skorupski et al. 2007, Klahn et al. 2011, Kagawa 
et al. 2015,  Mariani et al. 2015, Dervisis et al. 2017, Marlowe et al. 
2018) while the disseminated form is characterised by multiorgan 
involvement.
Certain breeds appear either predisposed or have increased fre-
quency of HS -most notably Bernese mountain dogs, flat-coated 
retrievers and Rottweilers. While disseminated HS appears most 
frequent in Bernese mountain dogs (Moore & Rosin 1986, 
Padgett et al. 1995, Rossi et al. 2009), Flat-coated retrievers 
present more commonly with the localised form, particularly 
the periarticular elbow site (Constantino-Casas et al. 2011). Pri-
mary pulmonary HS was first described in 19 Pembroke Welsh 
corgis in Japan (Kagawa et al. 2015). Recently, a case series of 
14 miniature schnauzers described a similar clinical presenta-
tion, in which 10 had localised disease and nine of 10 cases were 
diagnosed with primary pulmonary HS (Lenz et al. 2017). The 
median survival time of dogs receiving chemotherapy was only 
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19 days, although they received varied treatment protocols. One 
of the dogs underwent surgical excision of the primary mass and 
survived for 1620 days, suggesting a possible role for surgery. 
This was further explored by Marlowe et al. (2018) describing 
37 different breeds from multiple institutions diagnosed with 
primary pulmonary HS. Dogs undergoing surgery followed by 
adjuvant lomustine (CCNU)-based chemotherapy appeared to 
have longer survival in comparison to dogs receiving chemo-
therapy alone.
The objective of this retrospective, descriptive case series was 
to report clinical presentation and treatment outcomes in a larger 
number of miniature schnauzers diagnosed with HS. A second-
ary goal was to identify prognostic factors influencing progres-
sion-free survival (PFS) and overall survival time (OST).
MATERIALS AND METHODS
Medical records of miniature schnauzers diagnosed with HS 
between 2008 and 2019 at two referral centres in the UK were 
retrospectively reviewed. Information collected from the medi-
cal records included signalment, weight, date of diagnosis and 
treatment initiation, clinical signs at diagnosis including respira-
tory signs, physical examination findings, laboratory tests results 
[including complete blood count (CBC), serum biochemistry, 
urinalysis, coagulation tests], method of diagnosis, imaging find-
ings, sites affected, treatment type, response to treatment, date of 
first progression, rescue treatment and date of death.
Cases with cytological or histopathological diagnosis of HS 
were included. Fine-needle biopsy smears were stained with 
Modified Wright’s stain (Hematek Siemens) or Diff-Quik 
(Atom Scientific). Archived cytological slides of all aspi-
rated sites were reviewed by a single board-certified clinical 
pathologist if smears were available; otherwise, information 
was retrieved from the original cytology reports. Cases for 
which cytology was inconclusive had to have histopathology 
to confirm the diagnosis of HS. Available histopathology slides 
were reviewed by a resident-in-training under supervision of 
a board-certified anatomic pathologist. If possible, immuno-
histochemistry with CD18 was performed on archived tissue 
blocks, if not performed at the time of the initial diagnosis. 
Radiographs, CT and ultrasound findings, including the 
follow-up studies when available, were reviewed by a board-
certified radiologist.
Response to treatment was assessed by the clinician manag-
ing the case and, in most cases, was determined by clinical signs, 
but follow-up imaging was also examined when available. In 
cases evaluated by monitoring of clinical signs alone, resolution 
of all clinical signs from the initial presentation was classified as 
complete response (CR), improvement but without resolution 
of clinical signs was classified as partial response (PR) and no 
improvement in clinical signs was classified as progressive dis-
ease (PD). For dogs undergoing follow-up imaging, response 
was classified using Veterinary Cooperative Oncology Group 
(VCOG v1.1) RECIST criteria (Nguyen et al. 2015). A mini-
mum response duration of 21 days was required to determine 
response (CR and PR) and dogs that died or were euthanased 
before 21 days were considered non-responders.
For dogs with a positive response following any form of local 
or systemic treatment, outcomes were assessed by PFS and OST. 
PFS was calculated from the date of treatment initiation to the 
date of local tumour progression/recurrence, metastasis or death 
from any cause. OST was calculated from the date of treatment 
initiation to the date of death from any cause. Dogs that were 
euthanased at presentation were excluded from this analysis. 
Follow-up information was obtained by phone calls to referring 
veterinarians and owners when necessary. The study was granted 
ethical approval by the Clinical Research Ethical Review Board of 
the primary study institution (protocol number URN SR2019-
0237).
STATISTICAL ANALYSIS
Descriptive statistics were evaluated for all data variables. Cat-
egorical data (sex, anaemia, thrombocytopenia, hypoalbumi-
naemia, systemic and/or respiratory signs at initial presentation, 
primary site affected, anatomical distribution of lesions, other 
organs affected, pleural effusion, mediastinal involvement, 
method of diagnosis, type of treatment received) were pre-
sented as numbers and/or percentages. Continuous data (age, 
weight, PFS and OST) were expressed as median and range. The 
Kaplan–Meier curve was used to illustrate the OST. The data 
were described and analysed using SPSS statistics software, ver-
sion 18.0.
RESULTS
Signalment, clinical signs and bloodwork
Thirty dogs were included (Table 1). Overall, 16 dogs (53%) 
had respiratory signs at diagnosis. The most common findings 
on physical examination included muffled heart and lung sounds 
(n=8, 27%), tachypnoea (n=7, 23%), increased respiratory effort 
(n=5, 17%) and increased respiratory sounds on one/both sides 
of the thorax (n=5, 17%).
Table 1. Signalment and clinical signs at diagnosis (n=30)
Characteristics, median (range)
Age (year) 10.5 (3 to 12.3)
Weight (kg) 9.3 (6.7 to 20)
Sex (n)
Male 18
Female 12
Clinical signs (n)
Lethargy 19
Decreased appetite 18
Weight loss 4
Vomiting/diarrhoea 4
Cough 11
Dyspnoea 6
Tachypnoea 4
Neurological signs (seizure, trembling, paraparesis) 4
PU/PD 2
Uveitis 1
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Laboratory abnormalities at the time of diagnosis (CBC and 
biochemistry performed in 29 and 25 dogs, respectively) were 
non-specific and included neutrophilia (n=10, 34%), anaemia 
(n=8, 28%), thrombocytopenia (n=2, 7%), monocytosis (n=2, 
7%), mastocytaemia (n=2, 7%), hypoalbuminaemia (n=10, 
40%), elevation of creatine kinase activity (n=6, 24%), eleva-
tion of alanine aminotransferase activity (n=4, 16%), elevation 
of alkaline phosphatase activity (n=4, 16%) and free hypercal-
caemia (n=1, 4%).
Imaging findings and staging
All but one dog underwent some form of imaging. Twenty-nine of 
30 dogs underwent thoracic imaging including CT (n=20, 69%), 
radiographs (n=7, 24%) or ultrasound (n=2, 7%). Twenty-five 
dogs (83%) had abdominal imaging including CT (n=17, 68%) 
and ultrasound (n=8, 32%). Twenty-four of 29 (83%) dogs under-
going thoracic imaging had lung and/or mediastinal involvement. 
The anatomic distribution of thoracic lesions was recorded for dogs 
undergoing CT imaging. For the remaining dogs in which another 
imaging modality was performed, only limited information was 
extracted from the reports (Table 2). On CT, all lesions appeared as 
soft tissue-attenuating masses (19/20, 90%). In one dog undergo-
ing thoracic imaging no lung or mediastinal lesions were noted.
As part of staging, 11 dogs (37%) had sampling of the spleen 
(10 for cytological, and one for histopathological examination), 
which confirmed splenic involvement in four of these 11 dogs 
(36%). Twelve dogs (40%) underwent sampling of the liver (11 
for cytology and one for biopsies during post mortem examina-
tion) which confirmed HS involvement in three of these 12 dogs 
(25%). Bone marrow involvement was suspected in one dog with 
peripheral cytopenias, but was not confirmed. Based on physical 
examination and imaging findings, 21 dogs (70%) had a suspicion 
of extra-thoracic organ involvement (summarised in Table 3).
Cytological and histopathological review
Twenty dogs (67%) were diagnosed with HS based on cytology 
findings alone, and three (10%) exclusively by histopathology (with-
out prior cytology); seven (23%) dogs had both cytological and his-
topathological examination to reach final diagnosis.
Cytological review of the archived slides was performed in 
17 cases, 15 of which were consistent with HS. One case was 
diagnosed as anaplastic malignancy and one as mixed inflam-
mation, with HS not excluded. In both cases, the diagnosis of 
HS was subsequently confirmed on histopathology. Cytologi-
cally, smears diagnostic for HS contained variable numbers of 
neoplastic round to occasionally more fusiform cells, with oval 
to reniform nuclei, finely stippled to granular chromatin, promi-
nent nucleoli, and variable amounts of pale basophilic cytoplasm, 
often containing clear vacuoles (see Figs 1 and 2). Pleomorphism 
was typically marked, including moderate to marked anisocytosis 
and anisokaryosis, macrocytosis and karyomegaly, frequent bi- 
and multinucleation, often with intracellular anisokaryosis and 
occasional satellite nuclei; occasionally, nuclei of multinucleated 
giant cells were arranged peripherally. Nucleoli were of variable 
number, shape and size, including macronucleoli. Mitotic fig-
ures were observed in most cases, occasionally in high numbers, 
and often with aberrant forms. Erythrophagia was observed in 
13 cases but was mainly rare, and phagocytosis of leukocytes and 
cellular debris was found in five cases each. Rare cannibalism was 
noted in one case. Six aspirates had evidence of necrosis, and 
inflammation was recorded in 10 cases, including neutrophilic 
Table 2. Thoracic imaging findings and anatomical 
distribution of lesions in 29 dogs with thoracic imaging
Location Number affected  
(imaging modality)
Left cranial 0
Left caudal 1; 3% (CT)
Right cranial 0
Right middle 3; 10% (CT)
Right caudal 1; 3% (CT)
Accessory 1; 3% (CT)
More than one lung lobe on right 2; 7% (CT)
More than one lung lobe on left 1; 3% (CT)
All lung lobes 9; 30% (8 CT, 1 radiograph)
Lymphadenopathy 21; 72% (17 CT, 4 ultrasound)
Pleural effusion 4; 14% (1 CT, 1 radiograph, 2 
ultrasound)
Table 3. Distribution of lesions other than thoracic, based 
on physical examination and imaging findings
Location Number affected (confirmed on 
cytology and/or histopathology)
Liver 3 (3 confirmed)
Spleen 4 (4 confirmed)
Abdominal lymph nodes 10 (4 confirmed)
Intestinal mass 1 (1 confirmed)
Kidney(s) 2 (1 confirmed)
Peripheral lymph node 1 (1 confirmed)
Subcutaneous mass 1 (1 confirmed)
Brain 1 (1 confirmed)
Spinal cord 2 (1 confirmed)
Eye 1 (1 confirmed)
Lytic bone lesion 1 (1 confirmed)
Bone marrow 1 (not confirmed)
FIG 1. Fine needle biopsy sample of a mediastinal mass diagnosed 
as histiocytic sarcoma in a miniature schnauzer. Note prominent 
binucleation and multinucleation (arrows), as well as cytoplasmic 
vacuolation. Modified Wright’s stain, ×40 objective. Bar=20 μm
K. Purzycka et al.
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FIG 3. Tissue sections of an ocular (A) and renal (B) histiocytic sarcoma. Neoplastic round cells are highly pleomorphic with frequent multinucleated 
cells (arrowheads) and mitotic figures (arrows), including bizarre forms. H&E, ×40 objective
inflammation in nine, eosinophilic inflammation in four, lym-
phocytic inflammation in two.
Histopathological review was available in eight cases. It 
revealed a pleomorphic and densely cellular malignant round cell 
tumour. Neoplastic cells were generally arranged in patternless 
sheets and ranged from plump fusiform to polygonal with often 
abundant cytoplasm and multiple nuclei, including multinucle-
ated tumour giant cells in most cases. Mitotic figures were fre-
quently observed, including bizarre forms (Fig. 3A, B). Tumours 
from five dogs labelled strongly and specifically (membranous) 
for CD18 by immunohistochemistry (Fig. 4A, B). In another 
two cases, between 10 and 40% of neoplastic cells exhibited spe-
cific labelling for CD18 and were morphologically consistent 
with HS. In a single case the morphology alone was sufficient to 
make the diagnosis of HS.
Treatment outcome
Outcome of all dogs included in the study is summarised in 
Table 4. Two dogs (7%) received corticosteroids before diagno-
sis. Eight dogs (27%) were euthanased at the time of diagno-
sis and another three (10%) were euthanased within 3 days of 
diagnosis without any treatment. Three dogs (10%) underwent 
surgery: one enucleation for presumed primary ocular HS, one 
splenectomy for a primary splenic HS and one right caudal lung 
lobectomy along with tracheobronchial lymph node excision. 
The latter case received adjuvant lomustine following surgical 
excision. Thirteen dogs (43%) received treatment with lomus-
tine as a sole therapy and one additional dog received it follow-
ing surgery. Three dogs (10%) received palliative treatment with 
supportive medication including prednisolone and/or analgesia 
only. For dogs receiving lomustine, the median dose was 59 mg/
m2 (range: 48.7 to 73).
Of the 13 dogs that received lomustine for gross disease, 
RECIST response could be evaluated in six dogs; five had PR 
and one had PD. Clinical improvement was documented in 11 
of 13 dogs (85%). Following progression of HS in 11 cases, seven 
dogs received rescue chemotherapy with a variety of protocols 
including doxorubicin, epirubicin, vinorelbine, toceranib, chlo-
rambucil and masitnib. Information in the medical record was 
not detailed enough to classify the responses in all cases.
Eleven of 14 dogs (79%) receiving lomustine had CBC per-
formed after the first dose, where VCOG grade 1, 2, 3 and 4 
neutropenia was documented in two (18%), zero (0%), three 
(27%) and two (18%), respectively. Six dogs (43%) developed 
alanine aminotransferase activity elevation VCOG grade 2 in 
three (21%) and grade 3 in three (21%) dogs.
The median OST for all dogs that were not euthanased within 
the first few days from diagnosis was 117 days (range 10 to 790) 
(Fig. 5). The median PFS for dogs receiving lomustine in gross 
disease settings was 117 days (range 22 to 182) and the median 
OST was 130 days (range 39 to 790. Two dogs that underwent 
surgery alone survived 45 and 157 days, respectively. Three dogs 
FIG 2. Fine needle biopsy sample of a submandibular lymph node effaced 
by metastatic histiocytic sarcoma. Neoplastic round cells display 
moderate anisocytosis and -karyosis, as well as frequent binucleation 
and multiple prominent nucleoli. Two mitotic figures are present (arrows). 
Modified Wright’s stain, ×40 objective. Bar=20 μm
Histiocytic sarcoma in miniature schnauzers
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that received palliative treatment only had survived 10, 43 and 
89 days, respectively. One dog that underwent lung lobectomy 
followed by lomustine had PFS and OST of 463 and 501 days, 
respectively. Due to low number of cases in each group and selec-
tive application of different therapies, a meaningful statistical 
comparison between the treatment groups could not be per-
formed.
All dogs were dead at the end of the study period. All but three 
dogs died or were euthanased due to HS. One dog suffered from 
severe tracheal collapse concurrently and was euthanased due to 
severe respiratory distress while its tumour appeared stable. One 
dog developed progressive, cumulative thrombocytopenia (PLT 
<20×109/L), most likely due to chronic chlorambucil administra-
tion and was euthanased due to haemorrhagic diathesis. No bone 
marrow biopsy was performed. One dog developed seizures and, 
while CT of the brain did not find any mass effect, occult brain 
metastases were considered a possibility.
DISCUSSION
We found that the vast majority of miniature schnauzers with 
HS presented with intrathoracic disease, which is similar to find-
ings of Lenz and others (2017). This unique anatomical localisa-
tion of HS has been previously described in the Pembroke Welsh 
corgi (Kagawa et al. 2015). Localised HS has been shown to have 
good outcomes with local treatment and adjuvant chemotherapy 
(Skorupski et al. 2009) with a median survival time of 568 days. 
However, even with surgical excision, the recently reported sur-
vival for primary pulmonary HS (Marlowe et al. 2018) was worse 
(374 days). In our study, similar to many other studies (Kagawa 
et al. 2015, Lenz et al. 2017), the described disease course 
appeared aggressive and reported survival times were short. This 
is likely influenced by the lack of feasibility of local treatment. 
Benefit of surgery in pulmonary HS has been suggested by Mar-
lowe et al. (2018) but, in our study, even when localised to the 
thorax, the disease appeared advanced, often with multiple pul-
monary lesions and/or local lymph node involvement. This pre-
cluded surgical treatment in most of the cases, similarly to other 
reports (Marlowe et al. 2018) in which dogs with metastases 
were less likely to undergo surgery. Nevertheless, one of our cases 
underwent lung lobectomy and survived >500 days.
More than half of the dogs presented with respiratory signs. 
Previous studies have found that pulmonary HS affected the 
right middle lung lobe more commonly than other types of 
tumours (Tsai et al. 2012, Barrett et al. 2014) but other loca-
tions are frequently affected too (Marlowe et al. 2018). In our 
study, intrapulmonary lesions were widely distributed with one 
third of the cases having all lung lobes affected. Similar to previ-
ous reports, pleural effusion was not a common finding in our 
study, documented in 14% of previous cases (Shaiken et al. 1991, 
Schmidt et al. 1993, Tsai et al. 2012). Similar to other reports of 
HS (Tsai et al. 2012, Marlowe et al. 2018), we commonly noted 
intrathoracic lymphadenopathy (72%). In most of the cases, as 
the disease appeared advanced, we did not sample lymph nodes 
to confirm metastatic disease because it would not have changed 
the treatment.
Cytological and histopathological examination showed that 
similar to other reports (Brown et al. 1994, Kagawa et al. 2015, 
Erich et al. 2018) histiocytic cells typically appear highly pleo-
morphic and can be accompanied by various inflammatory cells.
Most of the dogs in our study experienced positive responses 
to lomustine. In five of six dogs undergoing follow-up imaging, 
PRs were documented, even in advanced cases, and 11 of 13 dogs 
clinically improved. Our response rates are considerably higher 
than previously described in HS (Skorupski et al. 2007, Rass-
nick et al. 2010, Cannon et al. 2015), which supports the use 
of lomustine in gross disease settings even in advanced disease. 
However, in our study, these responses were short-lived. Among 
dogs receiving lomustine, five (36%) experienced VCOG grade 3 
and 4 neutropenia. Due to the small size of miniature schnauzers, 
compounded formulations of lomustine were prescribed in all of 
FIG 4. Staining with anti-CD18 – Microscopic appearance of an ocular (A) and renal (B) histiocytic sarcoma. Neoplastic cells, including multinucleated 
cells, exhibit strong membranous labelling. Immunohistochemistry, anti-CD18 (canine), ×40 objective
K. Purzycka et al.
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the cases. Burton et al. (2016) documented considerably fewer 
episodes of neutropenia in dogs when compounded formula-
tions of lomustine were prescribed, comparing to Food and Drug 
Administration-approved formulations.
Our study has multiple limitations. For instance, due to the 
retrospective nature of this work, dogs neither underwent stan-
dard staging procedures nor follow-up evaluations or necropsy, 
therefore some observations were incomplete. As such, 29 of 
30 dogs underwent thoracic imaging and 24 of 30 dogs under-
went abdominal imaging. Therefore, if abdominal metastases 
or important intercurrent disease were overlooked then these 
could impact on survival making some conclusions unreliable. 
This, alongside the small numbers of dogs in different treatment 
groups, precluded meaningful analysis of factors influencing PFS 
and OST. However, we hope that our findings will pave the way 
for larger prospective studies examining the clinical progression 
and response to treatment of HS in this breed of dog. We were 
not able to retrieve all the cytology or biopsy slides for a stan-
dardised review of all cases, and furthermore 20 of the 30 dogs 
lacked histopathological confirmation of HS. Most cases dis-
played a characteristic cytological picture, enabling a high degree 
of confidence in the diagnosis but, in some instances, other sar-
comas or highly anaplastic carcinomas could not be ruled out 
with certainty. However, based on the clinical presentation and 
response to treatment with lomustine, we believe these differen-
tial diagnoses were unlikely.
This study describes the largest population of miniature 
schnauzers with HS, with clinical presentation supporting pre-
vious reports. Although responses to treatment were common, 
they were usually short-lived due to the aggressive nature of the 
disease. HS should be considered as a differential diagnosis in 
miniature schnauzers with pulmonary masses.
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